Clinical trials: Overweight, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Overweight
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Obesity & Overweight
Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity
This study investigates whether temporarily blocking the ghrelin receptor affects appetite and food intake in people with overweight or obesity.
- Trial name
- H24LEAP2 (NCT07897383)
- Testing
- Liver-expressed antimicrobial peptide 2
- Volunteers
- 18 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Overweight, Obesity
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
- Trial name
- NCT07502001
- Testing
- Acetaminophen, Metformin, Warfarin
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity and Obesity-related Medical Conditions
ESG With Fundal Mucosal Ablation
Endoscopic sleeve gastroplasty (ESG) have emerged as an effective primary endoscopic therapy for weight loss. While ESG recapitulates the configuration of a gastric sleeve, it has not yet been shown to achieve as robust weight…
- Trial name
- ESG-FUMA (NCT06790329)
- Testing
- Endoscopic sleeve gastroplasty with fundal mucosal ablation
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Overweight and Obesity
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity…
- Trial name
- NCT07857473
- Testing
- TE-8105 MAD Cohort 1, TE-8105 MAD Cohort 2, TE-8105 MAD Cohort 3
- Where
- 2 sites in Australia
- Volunteers
- 204 people
- Sponsor
- Immunwork, Inc.
Obesity, Interstitial Lung Disease
Feasibility of Semaglutide in Advanced Lung Disease
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1.
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary
- Trial name
- NCT05746039
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Obesity, Solid Neoplasm
Weight Management in Obese Cancer Patients During Curative Active Treatment
This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet…
- Conditions
- Obesity, Solid Neoplasm, Stage II-IV, Curative Treatment
- Trial name
- CANOBESE (NCT07058207)
- Testing
- Multimodal weight management program
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- ADIPO-CKD (NCT07309094)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Cardenal Herrera University
Obesity; Drug
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake.
- Trial name
- NCT06856928
- Testing
- Meal Challenge
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Severe Obesity
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
The SMART study is a 96-week, multicenter, randomized, double-blind, placebo-controlled superiority clinical trial. A total of 256 severe obesity patients are randomized 1:1 to either receive the bariatric surgery plus GCG/GLP-1…
- Trial name
- SMART (NCT07135141)
- Testing
- Sleeve gastrectomy plus early mazdutide initiation
- Where
- 14 sites in China
- Volunteers
- 256 people
- Sponsor
- Beijing Friendship Hospital
Obesity, Pain, Postoperative
Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery
The opioid consumption has exploded in the western world, and for some patient populations such as obese patients, patients with sleep apnoea or patients undergoing cancer treatment, opioid-sparing/ opioid-free strategies could…
- Trial name
- OS-PCC (NCT03756961)
- Testing
- Dexmedetomidine, Person-centred care (PCC), Esketamine
- Where
- 2 sites in Sweden
- Volunteers
- 220 people
- Sponsor
- Göteborg University
Obesity / Overweight
A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.
This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.
- Trial name
- NCT07794111
- Testing
- TQF6422 Injection
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Insulin Resistance, Type 2 Diabetes
Alpelisib Challenge Test (ACT)
The goal of this study is to test a potentially easier method for measuring how much insulin a person is capable of producing than the current gold-standard method, the "hyperglycemic clamp." Participants will come in for a…
- Conditions
- Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
- Trial name
- NCT07778524
- Testing
- Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Columbia University
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss…
- Trial name
- RESTORE (NCT05819853)
- Testing
- Semaglutide Injectable Product (Wegovy and/or Ozempic)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Colorado, Denver
Atrial Fibrillation, Obesity & Overweight
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to…
- Conditions
- Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
- Trial name
- TEAR-AF (NCT07715929)
- Testing
- Tirzepatide, Structured Lifestyle Intervention
- Volunteers
- 710 people
- Sponsor
- Yunlong Wang
Obesity
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy.
- Trial name
- NCT07633639
- Testing
- LSG-Semaglutide group, LSG-Mazdutide group, LSG-Tirzepatide group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- China-Japan Friendship Hospital
Insulin Resistance, Hyperinsulinemia
Human Models of Selective Insulin Resistance: Pancreatic Clamp
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with…
- Conditions
- Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT06558422
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University